Last reviewed · How we verify
Livalo, Ezetrol
Livalo (pitavastatin) is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis, while Ezetrol (ezetimibe) inhibits cholesterol absorption in the intestine.
Livalo (pitavastatin) is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis, while Ezetrol (ezetimibe) inhibits cholesterol absorption in the intestine. Used for Hypercholesterolemia and dyslipidemia, Primary prevention of cardiovascular disease, Secondary prevention in patients with established coronary artery disease.
At a glance
| Generic name | Livalo, Ezetrol |
|---|---|
| Also known as | Pitavastatin, Ezetimibe |
| Sponsor | JW Pharmaceutical |
| Drug class | Statin (pitavastatin) and cholesterol absorption inhibitor (ezetimibe) |
| Target | HMG-CoA reductase (pitavastatin); NPC1L1 transporter (ezetimibe) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Pitavastatin works as a statin by competitively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing LDL cholesterol levels. Ezetimibe selectively blocks the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, preventing dietary and biliary cholesterol absorption. Together, these agents provide complementary mechanisms to reduce circulating cholesterol levels.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Primary prevention of cardiovascular disease
- Secondary prevention in patients with established coronary artery disease
Common side effects
- Myalgia
- Elevated liver enzymes
- Headache
- Diarrhea
- Abdominal pain
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
- Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED) (PHASE1)
- To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Livalo, Ezetrol CI brief — competitive landscape report
- Livalo, Ezetrol updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI